Jaguar Health Regains Compliance With Nasdaq's Bid Price Requirement
Jaguar Health Regains Compliance With Nasdaq's Bid Price Requirement
JAGX's securities continue to be listed and traded on Nasdaq
JAGX證券仍在納斯達克上列出和交易
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024
Jaguar 將在 2024 年 7 月 23 日或之前公佈關鍵的三期試驗結果OnTarget 研究，一項針對受靶向治療的癌症患者的化療誘導腸道過度活躍（CIOB）預防性治療的關鍵第 3 期臨床試驗。投資者網絡研討會將於 2024 年 7 月 23 日或之前召開，屆時將更新 Jaguar 的腫瘤支持療法組合，並有 Jaguar 科學團隊、病人倡導者以及主要腫瘤治療相關腹瀉和口腔黏膜炎的專家參與
SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that Jaguar has regained compliance with Nasdaq's minimum bid price requirement.
加州舊金山/ACCESSWIRE/2024年6月26日/ jaguar health，inc。 （NASDAQ:JAGX）（"Jaguar"或"公司"）今天宣佈，2024年6月25日，公司收到了納斯達克股票市場有限責任公司（"納斯達克"）正式通知，Jaguar已恢復納斯達克最低報價要求的合規性。
"We are very happy that Jaguar has regained compliance with Nasdaq. We consider our Nasdaq listing an asset of the Company," said Lisa Conte, Jaguar's president and CEO. "A Jaguar investor webcast held on or before July 23, 2024 will provide updates on Jaguar's advancing cancer supportive care portfolio, and will include members of Jaguar's scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis."
"我們非常高興Jaguar已恢復符合納斯達克的要求。我們認爲我們的納斯達克上市是公司的資產，"Jaguar的總裁兼首席執行官Lisa Conte說。"在2024年7月23日之前舉行的Jaguar投資者網絡研討會將提供關於Jaguar正在推進的癌症支持護理組合的更新，並將包括Jaguar科學團隊、患者擁護者和兩種常見和難以忍受的癌症治療副作用專家的領先腫瘤學專家：CTD和口腔粘膜炎。"
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer also is the subject of Napo's phase 3 OnTarget clinical trial for preventive treatment of cancer therapy-related diarrhea (CTD). Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
關於Jaguar Health公司家族
Jaguar Health, Inc. (Jaguar) 是一家商業化藥品公司，專注於重點研究從熱帶雨林中可持續提取出來的治療人類和動物胃腸疾病的新型藥品，特別是與過度腸道緊張有關的消化道臨床症狀，包括慢性難治性腹瀉、緊迫感、腸失禁和痙攣性疼痛等症狀。Jaguar 家族藥品公司 Napo Pharmaceuticals (Napo) 專注於研發和商業化人類處方藥，以協助複雜疾病狀態下被忽視的胃腸症狀的必要的支持性治療和管理。Napo 的 crofelemer 已通過 FDA 批准，其商品名爲 Mytesi, 用於緩解接受抗逆轉錄病毒治療的 HIV/AIDS 成年患者的非傳染性腹瀉症狀。Crofelemer 還是 Napo 的 OnTarget 臨床三期試驗，用於預防治療腫瘤相關腹瀉（CTD）的主題以治療接受抗逆轉錄病毒療法的成年艾滋病毒/艾滋病患者的非感染性腹瀉症狀。Crofelemer也是Napo的第三期預防癌症治療相關腹瀉（CTD）的臨床試驗項目。Jaguar的家族公司Napo Therapeutic是一家成立於2021年的意大利公司，專注於擴大Crofelemer在歐洲的使用，特別是用於孤兒和/或罕見病。Jaguar Animal Health是方正證券的一個商標。由Jaguar和Filament Health Corp.組成的合資企業Magdalena Biosciences從Jaguar的患者倡導項目中脫穎而出。OnTarget 研究，一項針對受靶向治療的癌症患者的化療誘導腸道過度活躍（CIOB）預防性治療的關鍵第 3 期臨床試驗。創業公司Napo Therapeutics是一家意大利公司，由方正證券於2021年在米蘭成立，專注於擴大Crofelemer在歐洲的使用，特別是用於孤兒和/或罕見病。Entheogen Therapeutics Initiative（ETI），Jaguar 所開發的合資企業 Filament Health Corp. 和 Magdalena Biosciences 誕生的用於心理健康指標的植物衍生處方藥品的開發計劃。ETI（Endogenous Targeting of Isoprenylated Proteins）是一家由植物衍生的創新處方藥的開發公司，專注於治療心理健康領域。
For more information about:
Jaguar Health, visit https://jaguar.health
更多信息:
請訪問jaguar health。https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
請訪問Napo Pharmaceuticals。www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
訪問 Napo Therapeutics，網址爲 napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
訪問 Magdalena Biosciences，網址爲 magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
訪問 DRAGEN 專頁同上患者倡導計劃在此處makecancerlessshitty.com與此同時您也可以在X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will report the results of the OnTarget trial on or before July 23, 2024, and the expectation that Jaguar will hold an investor webcast on or before July 23, 2024 regarding updates on the Company's cancer supportive care portfolio. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
前瞻性聲明
本新聞稿中的某些聲明構成"前瞻性聲明"。這些包括有關Jaguar將在2024年7月23日或之前報告OnTarget試驗結果的聲明，以及Jaguar將在2024年7月23日或之前舉行投資者網絡研討會，並就公司的癌症支持護理組合更新。在某些情況下，您可以通過"可能"、"將"、"應該"、"預計"、"計劃"、"瞄準"、"預警"、"可能"、"有意"、"目標"、"項目"、"思考"、"相信"、"估計"、"預測"、"潛在"或"繼續"或這些術語的否定來確定前瞻性聲明或其他類似表達。本發佈中的前瞻性聲明僅是預測。Jaguar主要根據其對未來事件的當前期望和預測，就本發佈中的前瞻性聲明做出表述。這些前瞻性聲明僅截至本發佈日期，並且存在許多風險、不確定性和假設，其中一些無法預測或量化，而另一些超出了Jaguar的控制範圍。除適用法律要求外，Jaguar不打算公開更新或修訂本新聞稿中包含的任何前瞻性聲明，無論是基於任何新信息、未來事件、變化的情況還是其他原因。
CONTACT:
hello@jaguar.health
Jaguar-JAGX
聯繫人：
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health
資料來源：Jaguar Health
譯文內容由第三人軟體翻譯。